Treatment of Narcolepsy and Hypersomnia

Pharmacological Interventions

• The American Academy of Sleep Medicine suggests modafinil and armodafinil for treating narcolepsy and hypersomnia secondary to traumatic brain injury, with conditional recommendations for both medications 1
• Modafinil's mechanism of action involves enhancing activity in the hypothalamic wakefulness center, activating tuberomammillary nucleus neurons that release histamine, and activating hypothalamic neurons that release orexin/hypocretin, with strong supporting evidence from the National Comprehensive Cancer Network 2
• The recommended dose of modafinil is 200 mg daily, which has demonstrated improvement in fatigue levels in various conditions, as recommended by the National Comprehensive Cancer Network, with dose adjustments considering that higher doses (200-400 mg/day) may produce anxiety and stress-related symptoms, while lower doses (50-200 mg/day) may be better for managing concentration problems and fatigue with fewer stress-related side effects 2
• Modafinil can increase stress and anxiety in some individuals, with nervousness and anxiety among the most common adverse reactions reported in clinical trials that led to treatment discontinuation, and may reduce the efficacy of hormonal contraceptives, with rare but serious side effects, including Stevens-Johnson syndrome, as stated by the American Academy of Sleep Medicine and the National Comprehensive Cancer Network 3, 2
• The American Academy of Sleep Medicine strongly recommends idiopathic hypersomnia as an FDA-approved diagnosis for modafinil coverage, with required documentation of MSLT results and exclusion of other causes of hypersomnia, for patients ≥17 years old, and supports the use of modafinil for hypersomnia secondary to medical disorders (Parkinson's disease, traumatic brain injury, multiple sclerosis) and myotonic dystrophy with hypersomnia, with strong supporting evidence 1
• Modafinil is also indicated for narcolepsy, with documentation of Multiple Sleep Latency Test (MSLT) showing sleep-onset REM periods, evidence of excessive daytime sleepiness, and cataplexy documentation (when present) required, and for Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS), with polysomnography confirming diagnosis, documentation of adequate CPAP compliance, and evidence of residual sleepiness despite optimal CPAP therapy necessary, as stated by the American Academy of Sleep Medicine 1
• When prescribing modafinil, it is essential to monitor for development or worsening of anxiety, sleep disturbances, agitation, cardiovascular symptoms, and psychological changes, with pediatric use requiring special justification due to black box warnings, and documentation of discussion of risks/benefits necessary for patients with pregnancy or controlled substance use, as recommended by the American Academy of Sleep Medicine 1, 2
• Insurance companies typically require documentation of failure with or contraindication to first-line therapies, and evidence of clinical response and continued need at regular intervals for renewal, with a prescription from or consultation with a sleep specialist, neurologist, or psychiatrist may be required, as stated by the American Academy of Sleep Medicine 1

Special Considerations

• Stimulant medications, such as methylphenidate and amphetamine-based stimulants, are typically first-choice treatments for ADHD, working for 70-80% of patients, as recommended by the American Academy of Sleep Medicine and other authorities 4
• Non-stimulant options include bupropion, atomoxetine, guanfacine, clonidine, and viloxazine, with the gold standard for moderate to severe ADHD involving a combination of psychotherapy (particularly CBT) and medication, as stated by the American Academy of Sleep Medicine 4